New MS drug shows promise in reducing brain lesions

NCT ID NCT06564311

Ongoing Disease control Sponsor: Zenas BioPharma (USA), LLC Source: ClinicalTrials.gov ↗

First seen Nov 17, 2025 · Last updated May 01, 2026 · Updated 20 times

Summary

This study tests an experimental drug called obexelimab in 93 people with relapsing multiple sclerosis (MS). The goal is to see if it can reduce new brain lesions and relapses better than a placebo. Participants receive either the drug or a placebo, and their brain scans and symptoms are monitored over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

AZ Delta-Deltalaan 1

Roeselare, Belgium
Aalborg Universitetshospital

Aalborg, Denmark
Aqualine Clinical Research

Naples, Florida, 35105, United States
Attikon University General Hospital

Chaïdári, Greece
Barts Health NHS Trust

London, United Kingdom
Boster Center for MS

Columbus, Ohio, 43235, United States
Center for Neurological Disorders

Greenfield, Wisconsin, 53228, United States
Center for Neurology and Spine

Phoenix, Arizona, 85032, United States
Fakultni nemocnice u sv. Anny v Brne

Brno, Czechia
Fondazione Isituto G. Giglio di Cefalu

Cefalù, Italy
Fondazione PTV Policlinico Tor Vergata

Roma, Italy
General University Hospital Praha

Prague, Czechia
Holy Name Medical Center

Teaneck, New Jersey, 07666, United States
Hospipal La Fe Valencia

Valencia, Spain
Hospital Clinico San Carlos

Madrid, Spain
Hospital General Universitario Gregorio Marañon

Madrid, Spain
Hospital Regional Universitario de Malaga

Málaga, Spain
Hospital Regional Universitario de Malaga - Hospital General

Málaga, Spain
Hospital Universitario Virgen de La Arrixaca

Murcia, Spain
Hospital Virgen Macarena

Seville, Spain
Infusion Associates Plymouth

Plymouth, Minnesota, 55446, United States
Istituto Neurologico Mediterraneo Neuromed

Pozzilli, Italy
Klinicki bolnicki centar Zagreb

Zagreb, Croatia
Leicester General Hospital

Leicester, United Kingdom
M.A. LEK A.M. Maciejowsy Spolka Cywilna

Katowice, Poland
MS Center for Innovations in Care

St Louis, Missouri, 63131, United States
Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Morriston Hospital

Swansea, United Kingdom
Nemocnice Jihlava

Jihlava, Czechia
Neuro-logisch Wien

Vienna, Austria
Neurocentrum Bydgoszcz sp.z o.o.

Bydgoszcz, Poland
North Central Neurology

Cullman, Alabama, 35058, United States
North Texas Institute of Neurology and Headache

Plano, Texas, 75024, United States
People's Hospital of Xinjiang Uyaur Autonomous Region

Ürümqi, China
Perseverance Research Center

Scottsdale, Arizona, 85253, United States
Regina Berkovich MD PhD, Inc

West Hollywood, California, 90048, United States
Rehabilitation & MS Center, Noorderhart Hospital

Overpelt, Belgium
The First Affiliation Hospital of Soochow University

Suzhou, China
Tianjin Medical University General Hospital

Tianjin, China
Tiantan Hospital, Capital Medical University

Beijing, China
Tongji Hospital, Tongji Medical Center of HUST

Wuhan, China
University General Hospital of Larissa

Larissa, Greece
University of Florence

Florence, Italy
University of Massachusetts Medical School

Worcester, Massachusetts, 01655, United States
University of South Florida

Tampa, Florida, 33620, United States
Wielospecjalistyczne Centrum Medyczne Ibismed

Zabrze, Poland
Zanamed Medical Clinic Sp z o.o.

Lublin, Poland

Conditions

Explore the condition pages connected to this study.

RELAPSING MULTIPLE SCLEROSIS